#Australia #Sydney #Prostate Cancer #Clarity Pharmaceuticals #Co-PSMA

Clarity Pharmaceuticals to Showcase Co-PSMA Trial Results at EAU Annual Congress 2026

Clarity Pharmaceuticals, an innovative radiopharmaceutical company listed on ASX (CU6), has achieved a remarkable milestone with the acceptance of an abstract focusing on the Co-PSMA Investigator-Initiated Trial (IIT) for oral presentation at the European Association of Urology (EAU) Congress 2026. This event, renowned as Europe's largest urological conference, is scheduled to take place from March 13 to 16, 2026, in London, UK.

The primary focus of the Co-PSMA study, titled "Comparative performance of 64Copper [64Cu]-SAR-bisPSMA vs. 68Ga-PSMA-11 PET CT for the detection of prostate cancer recurrence in patients post-radical prostatectomy", is to assess the effectiveness of Clarity's diagnostic product, 64Cu-SAR-bisPSMA. This Phase II IIT, conducted by Prof. Louise Emmett at St Vincent's Hospital in Sydney, directly compares the diagnostic performance of 64Cu-SAR-bisPSMA against the standard-of-care (SOC), 68Ga-PSMA-11, within a sample of 50 patients with low prostate-specific antigen (PSA) levels eligible for curative salvage therapy.

According to previous findings, the Co-PSMA trial successfully met its primary endpoint, demonstrating that the 64Cu-SAR-bisPSMA PET/CT was capable of detecting a significantly higher number of lesions per patient than the SOC PET/CT scan. This critical outcome adds to a growing body of evidence that suggests the 64Cu-SAR-bisPSMA product can enhance prostate cancer detection, particularly among patients exhibiting low PSA levels where standard agents tend to show reduced sensitivity.

Dr. Alan Taylor, Executive Chairperson of Clarity, emphasized the importance of the findings, stating, "64Cu-SAR-bisPSMA has been designed meticulously at the benchtop to eliminate the limitations of current SOC PSMA imaging options. Within just seven years of its conception, we have progressed through laboratory tests, animal model investigations, and multiple clinical trials, proving its capability to significantly outperform competing products in clinical settings."

This oral presentation at EAU 2026 not only signifies recognition from the urology community but also underscores the transformative potential of the 64Cu-SAR-bisPSMA agent within prostate cancer diagnostics. With unwavering commitment to scientific rigor, Clarity Pharmaceuticals has gathered robust evidence validating the improved diagnostic performance of 64Cu-SAR-bisPSMA through extensive clinical trials and compassionate use instances.

The data presentation will reveal not only the capacity of 64Cu-SAR-bisPSMA to identify more lesions including smaller and potentially higher-risk indications but will also reinforce the established advantages over traditional SOC PSMA PET imaging agents. With two ongoing registrational Phase III trials and Fast Track Designations from the FDA, Clarity aims to solidify its position within the anticipated USD 3 billion PSMA PET imaging market by 2029.

In summary, the forthcoming presentation at the EAU Congress 2026 marks a significant advancement for Clarity Pharmaceuticals and the future of prostate cancer management, emphasizing their innovative approach through the SAR-bisPSMA technology. Prostate cancer, being the second-most common cancer among men on a global scale, necessitates the urgent attention and innovative solutions that Clarity Pharmaceuticals seeks to deliver through their diagnostic capabilities. As they prepare for their presentation, the details of the abstract will be unveiled in mid-February, further building anticipation among healthcare professionals and stakeholders within the oncology community.